Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg

BackgroundAlthough systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life phase is challenging. The aim of this study was to investigate the frequency and type o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Forschner, Andrea Lydia (VerfasserIn) , Kähler, Katharina C. (VerfasserIn) , Gschnell, Martin (VerfasserIn) , Langan, Ewan A. (VerfasserIn) , Weishaupt, Carsten (VerfasserIn) , Meiss, Frank (VerfasserIn) , Thoms, Kai-Martin (VerfasserIn) , Wahl, Renate U. (VerfasserIn) , Göppner, Daniela (VerfasserIn) , Garzarolli, Marlene (VerfasserIn) , Sachse, Michael (VerfasserIn) , Schlaak, Max (VerfasserIn) , Reitmajer, Markus (VerfasserIn) , Kellner, Ivonne (VerfasserIn) , Gesierich, Anja (VerfasserIn) , Mohr, Peter (VerfasserIn) , Meier, Friedegund (VerfasserIn) , von Wasielewski, Imke (VerfasserIn) , Herbst, Rudolf (VerfasserIn) , Utikal, Jochen (VerfasserIn) , Pföhler, Claudia (VerfasserIn) , Ulrich, Jens (VerfasserIn) , Terheyden, Patrick (VerfasserIn) , Kaatz, Martin (VerfasserIn) , Haferkamp, Sebastian (VerfasserIn) , Leiter, Ulrike (VerfasserIn) , Ugurel, Selma (VerfasserIn) , Weichenthal, Michael (VerfasserIn) , Berking, Carola (VerfasserIn) , Gutzmer, Ralf (VerfasserIn) , Schadendorf, Dirk (VerfasserIn) , Nanz, Lena (VerfasserIn) , Loquai, Carmen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 24 February 2025
In: Frontiers in immunology
Year: 2025, Jahrgang: 16, Pages: 01-09
ISSN:1664-3224
DOI:10.3389/fimmu.2025.1509886
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2025.1509886
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1509886/full
Volltext
Verfasserangaben:Andrea Forschner, Katharina C. Kähler, Martin Gschnell, Ewan A. Langan, Carsten Weishaupt, Frank Meiss, Kai-Martin Thoms, Renate U. Wahl, Daniela Göppner, Marlene Garzarolli, Michael Sachse, Max Schlaak, Markus Reitmajer, Ivonne Kellner, Anja Gesierich, Peter Mohr, Friedegund Meier, Imke von Wasielewski, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Patrick Terheyden, Martin Kaatz, Sebastian Haferkamp, Ulrike Leiter, Selma Ugurel, Michael Weichenthal, Carola Berking, Ralf Gutzmer, Dirk Schadendorf, Lena Nanz and Carmen Loquai

MARC

LEADER 00000caa a2200000 c 4500
001 1930135653
003 DE-627
005 20251111093349.0
007 cr uuu---uuuuu
008 250710s2025 xx |||||o 00| ||eng c
024 7 |a 10.3389/fimmu.2025.1509886  |2 doi 
035 |a (DE-627)1930135653 
035 |a (DE-599)KXP1930135653 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Forschner, Andrea Lydia  |d 1975-  |e VerfasserIn  |0 (DE-588)122718194  |0 (DE-627)706012437  |0 (DE-576)183547144  |4 aut 
245 1 0 |a Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg  |c Andrea Forschner, Katharina C. Kähler, Martin Gschnell, Ewan A. Langan, Carsten Weishaupt, Frank Meiss, Kai-Martin Thoms, Renate U. Wahl, Daniela Göppner, Marlene Garzarolli, Michael Sachse, Max Schlaak, Markus Reitmajer, Ivonne Kellner, Anja Gesierich, Peter Mohr, Friedegund Meier, Imke von Wasielewski, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Patrick Terheyden, Martin Kaatz, Sebastian Haferkamp, Ulrike Leiter, Selma Ugurel, Michael Weichenthal, Carola Berking, Ralf Gutzmer, Dirk Schadendorf, Lena Nanz and Carmen Loquai 
264 1 |c 24 February 2025 
300 |b Diagramme 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.07.2025 
520 |a BackgroundAlthough systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life phase is challenging. The aim of this study was to investigate the frequency and type of systemic therapy received by melanoma patients in their end-of-life phase.MethodsPatients with metastatic melanoma who had died between January 1, 2018 and October 31, 2022 were identified from the prospective multicenter skin cancer registry ADOReg. Study endpoints were percentage of patients who had been treated with systemic therapy within the last three months of life, timepoint of initiation of the last-line therapy, overall survival, treatment benefit and the incidence of treatment-related adverse events.ResultsIn total, 1067 patients from 46 skin cancer centers were included. Most of the patients (63%) had received immune checkpoint inhibitors (ICI) as last-line therapy, 22% targeted therapies (TT) and 12% chemotherapy (CTX). Comparing last-line ICI and TT, patients with TT were significantly more likely to benefit from treatment and had significantly fewer and milder treatment-related AE than patients with ICI. Even though two thirds of patients had received ICI as a last-line therapy, the majority of these patients (61%) had stopped therapy within the last 30 days of life, whereas the majority of patients with TT (66%) still continued their treatment to the end of life. We found markedly fewer patients with initiation of ICI within 30 days before their death (19%) compared to a historic cohort including patients who died in 2016 or 2017 (39%).ConclusionTreatment approaches near the end of life have markedly changed in skin cancer centers in Germany over recent years, with ICI prescribed less frequently in the end-of-life phase. In contrast, TT are frequently administered, even within the last 30 days of life. It should also be considered that discontinuation of TT can result in rapid tumor progression. Due to the oral administration and a low rate of severe toxicity, TT appear to be a suitable treatment option, even in the end-of-life situation of melanoma patients. 
650 4 |a BRAF and MEK inhibitors 
650 4 |a end of life 
650 4 |a immune checkpoint inhibitors 
650 4 |a ipilimumab 
650 4 |a melanoma 
650 4 |a nivolumab 
700 1 |a Kähler, Katharina C.  |e VerfasserIn  |4 aut 
700 1 |a Gschnell, Martin  |e VerfasserIn  |4 aut 
700 1 |a Langan, Ewan A.  |e VerfasserIn  |4 aut 
700 1 |a Weishaupt, Carsten  |d 1973-  |e VerfasserIn  |0 (DE-588)130499129  |0 (DE-627)502596430  |0 (DE-576)298232898  |4 aut 
700 1 |a Meiss, Frank  |e VerfasserIn  |4 aut 
700 1 |a Thoms, Kai-Martin  |e VerfasserIn  |4 aut 
700 1 |a Wahl, Renate U.  |e VerfasserIn  |4 aut 
700 1 |a Göppner, Daniela  |e VerfasserIn  |4 aut 
700 1 |a Garzarolli, Marlene  |e VerfasserIn  |4 aut 
700 1 |a Sachse, Michael  |e VerfasserIn  |4 aut 
700 1 |a Schlaak, Max  |e VerfasserIn  |4 aut 
700 1 |a Reitmajer, Markus  |e VerfasserIn  |4 aut 
700 1 |a Kellner, Ivonne  |e VerfasserIn  |4 aut 
700 1 |a Gesierich, Anja  |e VerfasserIn  |4 aut 
700 1 |a Mohr, Peter  |e VerfasserIn  |4 aut 
700 1 |a Meier, Friedegund  |e VerfasserIn  |4 aut 
700 1 |a von Wasielewski, Imke  |e VerfasserIn  |4 aut 
700 1 |a Herbst, Rudolf  |e VerfasserIn  |4 aut 
700 1 |a Utikal, Jochen  |d 1974-  |e VerfasserIn  |0 (DE-588)1026463750  |0 (DE-627)726765015  |0 (DE-576)371816580  |4 aut 
700 1 |a Pföhler, Claudia  |e VerfasserIn  |4 aut 
700 1 |a Ulrich, Jens  |e VerfasserIn  |4 aut 
700 1 |a Terheyden, Patrick  |e VerfasserIn  |4 aut 
700 1 |a Kaatz, Martin  |e VerfasserIn  |4 aut 
700 1 |a Haferkamp, Sebastian  |d 1978-  |e VerfasserIn  |0 (DE-588)132018330  |0 (DE-627)51684296X  |0 (DE-576)298896044  |4 aut 
700 1 |a Leiter, Ulrike  |e VerfasserIn  |4 aut 
700 1 |a Ugurel, Selma  |d 1971-  |e VerfasserIn  |0 (DE-588)122030923  |0 (DE-627)081693532  |0 (DE-576)293057567  |4 aut 
700 1 |a Weichenthal, Michael  |e VerfasserIn  |0 (DE-588)140953272  |0 (DE-627)623003848  |0 (DE-576)321514157  |4 aut 
700 1 |a Berking, Carola  |e VerfasserIn  |4 aut 
700 1 |a Gutzmer, Ralf  |d 1968-  |e VerfasserIn  |0 (DE-588)113713371  |0 (DE-627)502213558  |0 (DE-576)289772095  |4 aut 
700 1 |a Schadendorf, Dirk  |d 1960-  |e VerfasserIn  |0 (DE-588)11142576X  |0 (DE-627)499566076  |0 (DE-576)289702275  |4 aut 
700 1 |a Nanz, Lena  |e VerfasserIn  |4 aut 
700 1 |a Loquai, Carmen  |d 1974-  |e VerfasserIn  |0 (DE-588)122252500  |0 (DE-627)705832473  |0 (DE-576)293176094  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in immunology  |d Lausanne : Frontiers Media, 2010  |g 16(2025), Artikel-ID 1509886, Seite 01-09  |h Online-Ressource  |w (DE-627)657998354  |w (DE-600)2606827-8  |w (DE-576)343624834  |x 1664-3224  |7 nnas  |a Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg 
773 1 8 |g volume:16  |g year:2025  |g elocationid:1509886  |g pages:01-09  |g extent:9  |a Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg 
856 4 0 |u https://doi.org/10.3389/fimmu.2025.1509886  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1509886/full  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250710 
993 |a Article 
994 |a 2025 
998 |g 11142576X  |a Schadendorf, Dirk  |m 11142576X:Schadendorf, Dirk  |d 50000  |e 50000PS11142576X  |k 0/50000/  |p 31 
998 |g 122030923  |a Ugurel, Selma  |m 122030923:Ugurel, Selma  |d 60000  |e 60000PU122030923  |k 0/60000/  |p 27 
998 |g 1026463750  |a Utikal, Jochen  |m 1026463750:Utikal, Jochen  |d 60000  |e 60000PU1026463750  |k 0/60000/  |p 20 
999 |a KXP-PPN1930135653  |e 4744422322 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 10.07.2025"],"recId":"1930135653","title":[{"title_sort":"Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg","title":"Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg"}],"id":{"eki":["1930135653"],"doi":["10.3389/fimmu.2025.1509886"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"24 February 2025"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"relHost":[{"pubHistory":["1.2010 -"],"recId":"657998354","title":[{"title":"Frontiers in immunology","title_sort":"Frontiers in immunology"}],"id":{"issn":["1664-3224"],"eki":["657998354"],"zdb":["2606827-8"]},"disp":"Treatment at the end of life in patients with advanced melanoma$amulticenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegFrontiers in immunology","note":["Gesehen am 07.11.13"],"part":{"extent":"9","year":"2025","pages":"01-09","text":"16(2025), Artikel-ID 1509886, Seite 01-09","volume":"16"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisher":"Frontiers Media","dateIssuedKey":"2010","publisherPlace":"Lausanne","dateIssuedDisp":"2010-"}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"person":[{"roleDisplay":"VerfasserIn","family":"Forschner","given":"Andrea Lydia","role":"aut","display":"Forschner, Andrea Lydia"},{"role":"aut","display":"Kähler, Katharina C.","given":"Katharina C.","family":"Kähler","roleDisplay":"VerfasserIn"},{"given":"Martin","display":"Gschnell, Martin","role":"aut","roleDisplay":"VerfasserIn","family":"Gschnell"},{"roleDisplay":"VerfasserIn","family":"Langan","display":"Langan, Ewan A.","role":"aut","given":"Ewan A."},{"display":"Weishaupt, Carsten","role":"aut","given":"Carsten","roleDisplay":"VerfasserIn","family":"Weishaupt"},{"given":"Frank","display":"Meiss, Frank","role":"aut","family":"Meiss","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Thoms, Kai-Martin","given":"Kai-Martin","roleDisplay":"VerfasserIn","family":"Thoms"},{"given":"Renate U.","role":"aut","display":"Wahl, Renate U.","roleDisplay":"VerfasserIn","family":"Wahl"},{"family":"Göppner","roleDisplay":"VerfasserIn","given":"Daniela","role":"aut","display":"Göppner, Daniela"},{"roleDisplay":"VerfasserIn","family":"Garzarolli","given":"Marlene","role":"aut","display":"Garzarolli, Marlene"},{"roleDisplay":"VerfasserIn","family":"Sachse","display":"Sachse, Michael","role":"aut","given":"Michael"},{"roleDisplay":"VerfasserIn","family":"Schlaak","display":"Schlaak, Max","role":"aut","given":"Max"},{"family":"Reitmajer","roleDisplay":"VerfasserIn","display":"Reitmajer, Markus","role":"aut","given":"Markus"},{"role":"aut","display":"Kellner, Ivonne","given":"Ivonne","roleDisplay":"VerfasserIn","family":"Kellner"},{"display":"Gesierich, Anja","role":"aut","given":"Anja","roleDisplay":"VerfasserIn","family":"Gesierich"},{"given":"Peter","display":"Mohr, Peter","role":"aut","family":"Mohr","roleDisplay":"VerfasserIn"},{"given":"Friedegund","role":"aut","display":"Meier, Friedegund","family":"Meier","roleDisplay":"VerfasserIn"},{"family":"von Wasielewski","roleDisplay":"VerfasserIn","role":"aut","display":"von Wasielewski, Imke","given":"Imke"},{"roleDisplay":"VerfasserIn","family":"Herbst","given":"Rudolf","display":"Herbst, Rudolf","role":"aut"},{"given":"Jochen","role":"aut","display":"Utikal, Jochen","family":"Utikal","roleDisplay":"VerfasserIn"},{"given":"Claudia","role":"aut","display":"Pföhler, Claudia","roleDisplay":"VerfasserIn","family":"Pföhler"},{"given":"Jens","role":"aut","display":"Ulrich, Jens","family":"Ulrich","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Terheyden, Patrick","given":"Patrick","family":"Terheyden","roleDisplay":"VerfasserIn"},{"family":"Kaatz","roleDisplay":"VerfasserIn","given":"Martin","display":"Kaatz, Martin","role":"aut"},{"given":"Sebastian","role":"aut","display":"Haferkamp, Sebastian","roleDisplay":"VerfasserIn","family":"Haferkamp"},{"family":"Leiter","roleDisplay":"VerfasserIn","given":"Ulrike","role":"aut","display":"Leiter, Ulrike"},{"display":"Ugurel, Selma","role":"aut","given":"Selma","family":"Ugurel","roleDisplay":"VerfasserIn"},{"given":"Michael","role":"aut","display":"Weichenthal, Michael","family":"Weichenthal","roleDisplay":"VerfasserIn"},{"family":"Berking","roleDisplay":"VerfasserIn","given":"Carola","display":"Berking, Carola","role":"aut"},{"given":"Ralf","display":"Gutzmer, Ralf","role":"aut","roleDisplay":"VerfasserIn","family":"Gutzmer"},{"display":"Schadendorf, Dirk","role":"aut","given":"Dirk","roleDisplay":"VerfasserIn","family":"Schadendorf"},{"display":"Nanz, Lena","role":"aut","given":"Lena","roleDisplay":"VerfasserIn","family":"Nanz"},{"roleDisplay":"VerfasserIn","family":"Loquai","role":"aut","display":"Loquai, Carmen","given":"Carmen"}],"name":{"displayForm":["Andrea Forschner, Katharina C. Kähler, Martin Gschnell, Ewan A. Langan, Carsten Weishaupt, Frank Meiss, Kai-Martin Thoms, Renate U. Wahl, Daniela Göppner, Marlene Garzarolli, Michael Sachse, Max Schlaak, Markus Reitmajer, Ivonne Kellner, Anja Gesierich, Peter Mohr, Friedegund Meier, Imke von Wasielewski, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Patrick Terheyden, Martin Kaatz, Sebastian Haferkamp, Ulrike Leiter, Selma Ugurel, Michael Weichenthal, Carola Berking, Ralf Gutzmer, Dirk Schadendorf, Lena Nanz and Carmen Loquai"]},"physDesc":[{"noteIll":"Diagramme","extent":"9 S."}]} 
SRT |a FORSCHNERATREATMENTA2420